跳至主要内容
临床试验/NCT01358760
NCT01358760已完成3 期

Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy

EndoCeutics Inc.42 个研究点 分布在 2 个国家目标入组 450 人开始时间: 2011年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
450
试验地点
42
主要终点
Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

研究概览

简要总结

The purpose of this Phase III trial is to evaluate the efficacy of intravaginal dehydroepiandrosterone (DHEA) in postmenopausal women with vaginal atrophy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Postmenopausal women (non-hysterectomized or hysterectomized)
  • Women between 40 and 75 years of age
  • Willing to participate in the study and sign an informed consent
  • Women who have self-identified symptom(s) of vaginal atrophy
  • For non-hysterectomized women, willing to have endometrial biopsy at baseline and end of study

排除标准

  • Undiagnosed abnormal genital bleeding
  • Hypertension equal to or above 140/90 mm Hg
  • The administration of any investigational drug within 30 days of screening visit
  • Endometrial hyperplasia, cancer or endometrial histology showing proliferative, secretory or menstrual type characteristics at histologic evaluation of endometrial biopsy performed at screening

研究组 & 干预措施

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

0.25% DHEA

Experimental

干预措施: DHEA (Drug)

0.5% DHEA

Experimental

干预措施: DHEA (Drug)

结局指标

主要结局

Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

时间窗: Baseline and Week 12

The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.

Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Vaginal Dryness

时间窗: Baseline and Week 12

The severity of vaginal dryness was evaluated by a questionnaire filled out by women. The severity of dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.

Change From Baseline to Week 12 in Vaginal pH

时间窗: Baseline and Week 12

A pH strip fixed on an Ayre spatula (or equivalent) was applied directly to the lateral wall of the vagina. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear

时间窗: Baseline and Week 12

The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.

次要结局

  • Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity(Baseline and Week 12)
  • Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness(Baseline and Week 12)
  • Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color(Baseline and Week 12)
  • Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions(Baseline and Week 12)
  • Change From Baseline to Week 12 in Severity of Dyspareunia(Baseline and Week 12)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (42)

Loading locations...

相似试验

Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy | 临床试验